AstraZeneca, one of the world’s leading pharmaceutical companies, invested $700 million for an inhaled medicines manufacturing site in Qingdao City, Shandong Province last year. The investment has shown the British biopharmaceutical giant’s commitment to the Chinese market, as its executive vice president Leon Wang stated in an interview with CGTN host Lincoln Humphries that “China is the best location for innovation”.
Breaking
Empowering Minds Through Informed Choices